Ver­sant pulls the wraps off of near­ly $1B in 3 new funds out to build the next fleet of biotech star­tups. And this new gen­er­a­tion is built for speed

Brad Bol­zon has an apol­o­gy to of­fer by way of in­tro­duc­ing a set of 3 new funds that to­geth­er pack a $950 mil­lion wal­lop in new biotech cre­ation and growth.

“I want to apol­o­gize,” says the Ver­sant chair­man and man­ag­ing part­ner, laugh­ing a lit­tle in the in­tro, “that we don’t have any­thing fan­cy or flashy to tell you about our new fund. Same team, around the same amount of cap­i­tal, same in­vest­ment strat­e­gy. If it ain’t broke, don’t fix it.”

But then there’s the flip side, where every­thing has changed. Or at least speed­ed in­to a rel­a­tive blur. Here’s Bol­zon:

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER